Preprint from Northwestern University Highlights Complementary Proteomic Analysis of Interleukin-6 Using Next-Generation Protein Sequencing™ and Mass Spectrometry

$QSI
Industrial Machinery/Components
Industrials
Get the next $QSI alert in real time by email

Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, announces a newly released preprint from researchers at Northwestern University, titled "Next-Generation Protein Sequencing and individual ion mass spectrometry enable complementary analysis of interleukin-6." The publication demonstrates the power of combining two cutting-edge technologies, Quantum-Si's Next-Generation Protein Sequencing™ (NGPS™) on Platinum®, and Individual Ion Mass Spectrometry (I2MS), to achieve a detailed analysis of key regions of the cytokine interleukin-6 (IL-6).

IL-6 is a key immune regulator and therapeutic target; however, its proteoform diversity can present significant analytical challenges. This study demonstrates how NGPS and I2MS provide complementary insights into the amino acid sequence, post-translational modifications, and proteoform variation of IL-6, paving the way for deeper understanding and potential therapeutic innovation.

"This preprint highlights the potential of merging Next-Generation Protein Sequencing with individual ion mass spectrometry," said Neil Kelleher, Ph.D., Professor at Northwestern University and senior author of the study. "By combining these methods, we can capture a fuller picture of IL-6 proteoforms, which is critical for advancing therapeutic innovation."

Key Findings:

  • NGPS provided single amino acid resolution for IL-6 peptide fragments critical to receptor binding and function, resolving regions with low sequence coverage by mass spectrometry.
  • I2MS enabled intact proteoform detection and localized modifications, including glycosylation, within regions involved in IL-6 signaling.
  • Together these technologies provide high sequence coverage of overlapping and distinct regions of IL-6, offering a more comprehensive view of its structural and functional diversity.

"This study underscores the immense challenge of characterizing proteoforms, which has long been a barrier to developing novel therapies," said Jeff Hawkins, President and Chief Executive Officer of Quantum-Si. "By integrating Next-Generation Protein Sequencing into one of the world's leading proteomics labs, we're enabling new insights into IL-6, to advance therapeutic research. These findings highlight the transformative potential of combining NGPS with traditional methods to explore proteoforms with single amino acid precision in complex diseases like cancer and autoimmune disorders."

To read the preprint visit: Next-Generation Protein Sequencing and individual ion mass spectrometry enable complementary analysis of interleukin-6 | Quantum-Si

About Quantum-Si Incorporated

Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company's Platinum® line of instruments enables Next-Gen Protein Sequencing™ that advances proteomic research, drug discovery, and diagnostics beyond what has been possible with existing proteomic tools. Learn more at quantum-si.com or follow us on LinkedIn or X.

Forward Looking Statements

This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company's expectations with respect to future performance and development and commercialization of products and services, its anticipated cash runway and its financial guidance for the full year 2024. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the inability to maintain the listing of the Company's Class A common stock on The Nasdaq Stock Market; the ability of the Company to grow and manage growth profitably and retain its key employees; the Company's ongoing leadership transitions; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company's product development and commercialization activities; the commercialization and adoption of the Company's existing products and the success of any product the Company may offer in the future; the potential attributes and benefits of the Company's commercialized Platinum® protein sequencing instruments and kits and the Company's other products once commercialized; the Company's ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company's ability to identify, in-license or acquire additional technology; the Company's ability to maintain its existing lease, license, manufacture and supply agreements; the Company's ability to compete with other companies currently marketing or engaged in the development or commercialization of products and services that serve customers engaged in proteomic analysis, many of which have greater financial and marketing resources than the Company; the size and growth potential of the markets for the Company's products and services, and its ability to serve those markets once commercialized, either alone or in partnership with others; the Company's estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company's financial performance; and other risks and uncertainties described under "Risk Factors" in the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

Investor Contact

Jeff Keyes

Chief Financial Officer

ir@quantum-si.com

Media Contact

Katherine Atkinson

SVP, Commercial Marketing

media@quantum-si.com

Get the next $QSI alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$QSI

DatePrice TargetRatingAnalyst
2/7/2025$3.75Buy
Alliance Global Partners
12/8/2023$3.00Buy
H.C. Wainwright
9/25/2023$3.50 → $2.00Buy → Hold
Canaccord Genuity
10/20/2021$13.00Buy
Canaccord Genuity
More analyst ratings

$QSI
Press Releases

Fastest customizable press release news feed in the world

See more
  • Quantum-Si Begins Shipping Platinum® Pro, Advancing Accessibility in Next-Gen Protein Sequencing™

    Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, announces the start of shipments for its latest benchtop sequencer, Platinum® Pro. This groundbreaking instrument offers protein analysis with single-molecule precision, aiming to make Next-Gen Protein Sequencing™ more accessible to laboratories worldwide. Platinum Pro delivers a comprehensive solution for sequencing and analyzing proteins through a simple, integrated workflow. Building upon the foundation of innovation established by the original Platinum, the new system introduces advanced features tailored to the evolving needs of researchers and biopharmaceutical customers. Key

    $QSI
    Industrial Machinery/Components
    Industrials
  • Quantum-Si to Participate in DNAnexus Webinar on Large Scale Proteomics in Multi-Omics Research

    Validate multi-omics findings at the single-molecule level with Next-Gen Protein Sequencing™ Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, announces participation in an upcoming DNAnexus webinar focused on the role of proteomics in multi-omics research. This discussion will explore how the integration of proteomics data with other omics datasets is driving new discoveries in disease research, including cancer. When: March 25, 2025, at 8 a.m. PT/11 a.m. ET Attendees will learn about: The growing impact of proteomics in multi-omics analysis Applications for cancer and other disease research Technologies and strategies fo

    $QSI
    Industrial Machinery/Components
    Industrials
  • Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced that the Compensation Committee of Quantum-Si's Board of Directors has granted 20,833 restricted stock units ("RSUs") to new employees under the Company's previously adopted Quantum-Si Incorporated 2023 Inducement Equity Incentive Plan, as amended (the "2023 Inducement Plan"). The RSUs were granted as an inducement material to the new employees becoming an employee of Quantum-Si in accordance with Nasdaq Listing Rule 5635(c)(4). The 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Quantum-Si

    $QSI
    Industrial Machinery/Components
    Industrials

$QSI
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$QSI
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$QSI
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$QSI
SEC Filings

See more

$QSI
Leadership Updates

Live Leadership Updates

See more
  • Quantum-Si Appoints Former Bio-Techne President and CEO, Chuck Kummeth, to serve as independent Chairman of the Board of Directors

    Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced the appointment of Charles ("Chuck") Kummeth to the role of independent Chairman of the Board, effective May 27, 2024. Mr. Kummeth has over 35 years of leadership experience in Life Sciences most recently as President and CEO of Bio-Techne. During Mr. Kummeth's tenure at Bio-Techne, he oversaw tremendous growth across all aspects of the business including annual revenue growth from $300M to over $1.1B, growth in the employee base from 800 to over 3,000, and the successful execution of 19 acquisitions, all while maintaining a 35% or better EBITDA level. Under Mr. Ku

    $QSI
    Industrial Machinery/Components
    Industrials
  • Quantum-Si Appoints Former Illumina and Cisco Systems Executive, Paula Dowdy, to its Board of Directors

    Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing CompanyTM, today announced the appointment of Paula Dowdy, a senior executive with more than 35 years of experience across life sciences, enterprise software, and technology industries, to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240321183506/en/Paula Dowdy (Photo: Business Wire) Ms. Dowdy currently serves on the Board of Directors for SPT Labtech, a world leading lab automation tools company based in the UK and is an advisor at EQT Life Sciences, one of Europe's leading investors targeting innovative

    $QSI
    Industrial Machinery/Components
    Industrials
  • Quantum-Si Introduces World's First Next-Generation Protein Sequencer™ in Japan with Addition of New Distributor

    Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced that it has entered into an agreement with a new distributor who will make the company's protein sequencing instrument, Platinum® available for the first time in Japan. TOMY Digital Biology Co., Ltd., a renowned importer and distributor with a rich history dating back to the 1950s, will distribute Quantum-Si's next-generation protein sequencer™ and associated consumables throughout Japan. "Working with Quantum-Si marks a pivotal moment for TOMY Digital Biology, aligning with our commitment to advancing life sciences. We're poised to empower Japanese researchers wit

    $QSI
    Industrial Machinery/Components
    Industrials

$QSI
Financials

Live finance-specific insights

See more
  • Quantum-Si Reports Fourth Quarter and Full Year 2024 Financial Results

    Achieves First Quarterly Revenue Over $1 Million Completes Capital Raises of $86 Million Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced financial results for the fourth quarter and full year ended December 31, 2024. Press Release Highlights Reported revenue of $1.2 million for the fourth quarter of 2024 and $3.1 million for the full year 2024 (representing a 183% full year-over-year growth) Raised capital of over $86 million between the fourth quarter of 2024 and first week of 2025 (extending cash runway into the second half of 2027) Announced the launch of Platinum® Pro in January 2025, with shipp

    $QSI
    Industrial Machinery/Components
    Industrials
  • Quantum-Si to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

    Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced that it will report financial results for the fourth quarter and full year 2024 on Monday, March 3, 2025. Jeff Hawkins, President and Chief Executive Officer, and Jeff Keyes, Chief Financial Officer, will host a conference call to discuss financial results and provide a business update on the same day at 4:30 PM ET. Individuals interested in listening to the conference call may do so by joining the live webcast on the Investors section of the Quantum-Si website under Events and Presentations. Alternatively, individuals can register here to receive a dial-in numbe

    $QSI
    Industrial Machinery/Components
    Industrials
  • Quantum-Si Reports Third Quarter 2024 Financial Results

    Sales Pipeline is Accelerating and New Kits Remain on Track for Q4 Launch Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced financial results for the third quarter ended September 30, 2024. Press Release Highlights Reported revenue of $787,000 for the third quarter of 2024 Announced that Liberate Bio has integrated Platinum® Next-Generation Sequencing into their platform for developing novel gene therapies with improved targeting capabilities Announced appointments of industry veteran Todd Bennett as Chief Commercial Officer ("CCO"), John Vieceli, Ph.D. as Chief Product Officer and Lindsay Thompson as C

    $QSI
    Industrial Machinery/Components
    Industrials

$QSI
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more